AstraZeneca secures global rights to novel lung cancer drug Zegfrovy in $1.5 billion deal with Dizal Pharmaceutical
LONDON: AstraZeneca has signed an exclusive global licensing agreement for Zegfrovy (sunvozertinib), a novel oral EGFR inhibitor for lung cancer patients with exon 20 insertion mutations. In a landmark deal valued at up to $1.5 billion, AstraZeneca has entered into an exclusive…